Issue Date: March 14, 2016 | Web Date: March 11, 2016
UCLA gets windfall from Xtandi rights
The University of California, Los Angeles, has joined an elite group of academic institutions to hit the drug discovery jackpot. Royalty Pharma, a company that buys drug royalty rights, has paid $1.14 billion for part of the royalty rights for Medivation’s prostate cancer drug Xtandi, which was discovered by UCLA chemist Michael Jung and physician Charles Sawyers.
The university will receive about half of that sum. Also benefiting are UCLA’s chemistry department, the inventors, and . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society